Chronic Myelogenous Leukemia

Oncology
16
Pipeline Programs
10
Companies
14
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
1
8
0
1
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
4100%
+ 12 programs with unclassified modality

On Market (1)

Approved therapies currently available

Novartis
SCEMBLIXApproved
asciminib
Novartis
oral2021

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
4 programs
1
1
1
GleevecPhase 41 trial
AsciminibPhase 3Small Molecule1 trial
Asciminib single agentPhase 21 trial
nilotinibN/ASmall Molecule1 trial
Active Trials
NCT00413270No Longer Available
NCT07354074Not Yet Recruiting50Est. Feb 2033
NCT03106779Completed233Est. Dec 2024
+1 more trials
Astex Pharmaceuticals
Astex PharmaceuticalsUK - Cambridge
3 programs
3
decitabinePhase 2
decitabinePhase 21 trial
decitabinePhase 2
Active Trials
NCT00042016Completed
E
EisaiChina - Liaoning
2 programs
2
decitabinePhase 21 trial
decitabinePhase 21 trial
Active Trials
NCT00041990Completed40
NCT00042003Completed40
Alliance Pharmaceuticals
1 program
1
GleevecPhase 21 trial
Active Trials
NCT01011998Withdrawn0Est. Jul 2010
Abiogen
AbiogenItaly - Pisa
1 program
1
Imatinib MesylatePhase 21 trial
Active Trials
NCT00415909TerminatedEst. May 2013
Bristol Myers Squibb
1 program
1
dasatinibPhase 1/2Small Molecule1 trial
Active Trials
NCT01030718Completed54Est. Jun 2009
Teva
TevaIsrael - Petach Tikva
1 program
1
Arsenic trioxidePhase 11 trial
Active Trials
NCT01397734Terminated7Est. Aug 2018
M&
Merck & Co.RAHWAY, NJ
1 program
1
MK0457Phase 11 trial
Active Trials
NCT00500006Terminated3Est. Nov 2007
Takeda
TakedaTOKYO, Japan
1 program
1
PonatinibPhase 1Small Molecule1 trial
Active Trials
NCT00660920Completed81Est. May 2016
CT
1 program
1
TQB3911 tabletsPhase 11 trial
Active Trials
NCT06672263Not Yet RecruitingEst. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
NovartisGleevec
NovartisAsciminib
NovartisAsciminib single agent
Alliance PharmaceuticalsGleevec
AbiogenImatinib Mesylate
Astex Pharmaceuticalsdecitabine
Eisaidecitabine
Eisaidecitabine
Bristol Myers Squibbdasatinib
Chia Tai TianQing Pharmaceutical GroupTQB3911 tablets
TevaArsenic trioxide
TakedaPonatinib
Merck & Co.MK0457
Novartisnilotinib

Clinical Trials (14)

Total enrollment: 620 patients across 14 trials

NCT00081926NovartisGleevec

Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Start: Oct 2003Est. completion: Mar 2007112 patients
Phase 4Completed
NCT03106779NovartisAsciminib

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

Start: Oct 2017Est. completion: Dec 2024233 patients
Phase 3Completed
NCT07354074NovartisAsciminib single agent

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Start: Jun 2026Est. completion: Feb 203350 patients
Phase 2Not Yet Recruiting
NCT01011998Alliance PharmaceuticalsGleevec

A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML)

Start: Sep 2009Est. completion: Jul 20100
Phase 2Withdrawn
NCT00415909AbiogenImatinib Mesylate

TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients

Start: Dec 2006Est. completion: May 2013
Phase 2Terminated
NCT00042016Astex Pharmaceuticalsdecitabine

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Start: Jul 2002
Phase 2Completed
NCT00041990Eisaidecitabine

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Start: Jul 200240 patients
Phase 2Completed
NCT00042003Eisaidecitabine

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Start: Jul 200240 patients
Phase 2Completed
NCT01030718Bristol Myers Squibbdasatinib

Rollover Study of BMS-354825 in Patients With CML and Ph+ALL

Start: Jan 2006Est. completion: Jun 200954 patients
Phase 1/2Completed
NCT06672263Chia Tai TianQing Pharmaceutical GroupTQB3911 tablets

A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia

Start: Nov 2024Est. completion: Dec 2026
Phase 1Not Yet Recruiting
NCT01397734TevaArsenic trioxide

Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)

Start: Sep 2011Est. completion: Aug 20187 patients
Phase 1Terminated
NCT00660920TakedaPonatinib

Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies

Start: Jun 2008Est. completion: May 201681 patients
Phase 1Completed
NCT00500006Merck & Co.MK0457

A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)

Start: Oct 2007Est. completion: Nov 20073 patients
Phase 1Terminated
NCT00413270Novartisnilotinib

Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

Start: Dec 2006
N/ANo Longer Available

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
10 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)